Elanco Animal Health(NYSE) ELAN

Market Cap$13.17B

Since IPO (2018)-27%

5 Year-28%

1 Year+93%

1 Month+9%

$26.42

-0.15%

-0.04Today

After hours$26.38-$0.04 (-0.15%)

Elanco Animal Health last closing stock price
Metric	Price	Date
Last close	USD 26.37	2026-07-31

Elanco Animal Health stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+5.86%	USD 24.91	2026-07-24
1 month	+9.46%	USD 24.09	2026-07-01
3 month	+17.15%	USD 22.51	2026-05-01
Year to date	+16.53%	USD 22.63	2025-12-31
1 year	+92.76%	USD 13.68	2025-07-31
3 year	+120.3%	USD 11.97	2023-08-01
5 year	-27.69%	USD 36.47	2021-07-30
Since inception	-26.75%	USD 36.00	2018-09-20

Elanco Animal Health Financials at a Glance

Market Cap

$13.17B

Revenue (TTM)

$4.89B

Net Income (TTM)

-$242.00M

EPS (TTM)

-$0.49

P/E Ratio

-53.92

Dividend

$0.00

Beta (Volatility)

1.25 (Average)

Dividend

$0.00

Beta (Volatility)

1.25 (Average)

Price

$26.42

Volume

5,193,856

Open

$26.46

Price

$26.42

Volume

5,193,856

Open

$26.46

Previous Close

$26.37

Daily Range

$25.77 - $26.47

52-Week Range

$13.75 - $27.72

Estimated Earnings Date

Aug 5, 2026

Dividend

$0.00

Beta (Volatility)

1.25 (Average)

Price

$26.42

Volume

5,193,856

Open

$26.46

Previous Close

$26.37

Daily Range

$25.77 - $26.47

52-Week Range

$13.75 - $27.72

Estimated Earnings Date

Aug 5, 2026

ELAN News

Page 1

ELAN: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Elanco Animal Health

Elanco helps farmers and pet owners keep animals healthy and free from disease. The company makes medicines and vaccines for pets and livestock in over 90 countries. These products help protect the food supply and improve the lives of household companions.

What Animals Need

Advantage Family: Oral and topical treatments for dogs and cats that prevent fleas, ticks, and heartworms; represents 10% of revenue.
Seresto: Long-acting collars that kill and repel pests for up to eight months.
Credelio Family: Monthly chewable tablets for cats and dogs that treat internal and external parasites.
Rumensin: Additive that improves feed efficiency and prevents disease in cattle.
Maxiban and Monteban: Poultry products designed to prevent intestinal infections.

Strategic Moves and Growth

Acquired Bayer Animal Health in August 2020 to expand its global reach and product scale.
Launched Zenrelia in 2024 as a new oral tablet for skin allergies in dogs.
Introduced Credelio Quattro in January 2025 to provide broad protection against several types of worms and pests.
Initiated a restructuring plan in December 2025 to optimize the manufacturing and research footprint by 2026.

A Global Network for Innovation

The company maintains 16 manufacturing sites and over 1,000 employees dedicated to research and development across international centers of excellence. Its omnichannel distribution strategy reaches customers through veterinary clinics, retail stores, and online platforms.

The Recent Numbers

Revenue reached $1.1 billion in Q4 2025, up 12.2% from Q4 2024.
Operating income rose to $19 million in Q4 2025, an increase of 137.5% year-over-year.
Free cash flow was $46 million in Q4 2025, down 62.9% from $124 million in Q4 2024.
Net income fell to a loss of $276 million in Q4 2025, down 3350% from a $8 million loss in Q4 2024.

Bottom Line

Elanco has transitioned from a division of Eli Lilly and Company into an independent global leader in animal health. Through significant acquisitions and a steady pipeline of new medicines, it continues to adapt its business across the pet and livestock markets.

AI Generated • Apr 20, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

9,900

CEO

Jeffrey N. Simmons

Website

www.elanco.com

Headquarters

Indianapolis, IN 46221, US

ELAN Financials

Key Financial Metrics (TTM)

Gross Margin

49.44%

Operating Margin

8.95%

Net Income Margin

-4.95%

Return on Equity

-3.64%

Return on Capital

2.39%

Return on Assets

-1.83%

Earnings Yield

-1.85%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$13.17B

Shares Outstanding

499.45M

Volume

5.19M

Avg. Volume

5.89M

Financials (TTM)

Gross Profit

$2.42B

Operating Income

$438.00M

EBITDA

$764.00M

Operating Cash Flow

$577.00M

Capital Expenditure

-$262.00M

Free Cash Flow

$315.00M

Cash & ST Invst.

$428.00M

Total Debt

$3.99B

Elanco Animal Health Performance Analysis

Elanco Animal Health annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 4,411,000,000	-7.4%
2023	2023-12-31	USD 4,417,000,000	0.1%
2024	2024-12-31	USD 4,439,000,000	0.5%
2025	2025-12-31	USD 4,715,000,000	6.2%

Elanco Animal Health sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	4.0%
Q3	2025-09-30	-8.4%
Q4	2025-12-31	0.6%
Q1	2026-03-31	19.8%

Elanco Animal Health annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -0.16	-83.9%
2023	2023-12-31	USD -2.50	1465.7%
2024	2024-12-31	USD 0.68	N/A
2025	2025-12-31	USD -0.47	N/A

Elanco Animal Health sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-82.9%
Q3	2025-09-30	-415.3%
Q4	2025-12-31	-685.7%
Q1	2026-03-31	120.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$1.37B

+14.9%

Gross Profit

$785.00M

+41.2%

Gross Margin

57.26%

N/A

Market Cap

$13.17B

N/A

Market Cap/Employee

$1.33M

N/A

Employees

9,900

N/A

Net Income

$57.00M

-14.9%

EBITDA

$316.00M

+15.3%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$428.00M

-12.1%

Total Debt

$3.99B

-9.2%

Accounts Receivable

$1.15B

+8.9%

Inventory

$1.72B

+7.9%

Long Term Debt

$3.92B

-10.0%

Short Term Debt

$73.00M

+65.9%

Return on Assets

-1.83%

N/A

Return on Invested Capital

3.79%

N/A

Free Cash Flow

-$38.00M

+44.9%

Operating Cash Flow

$13.00M

+425.0%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

RVTYRevvity, Inc.

RVTYRevvity, Inc.$112.52-0.90%

ALGNAlign Technology, Inc.

ALGNAlign Technology, Inc.$169.16-2.45%

SOLVSolventum Corporation

SOLVSolventum Corporation$85.44-1.59%

EHCEncompass Health Corporation

EHCEncompass Health Corporation$111.07+0.16%

ENSGThe Ensign Group, Inc.

ENSGThe Ensign Group, Inc.$178.16-0.37%

RDYDr. Reddy's Laboratories Limited

RDYDr. Reddy's Laboratories Limited$11.85+0.17%

NBIXNeurocrine Biosciences, Inc.

NBIXNeurocrine Biosciences, Inc.$166.80-10.08%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NVDANvidia

NVDANvidia$200.75+0.03%

AAPLApple

AAPLApple$308.91-0.07%

AMZNAmazon

AMZNAmazon$271.58+0.15%

INTCIntel

INTCIntel$90.20-0.01%

FCUVFocus Universal

FCUVFocus Universal$11.60+5.17%

NOKNokia

NOKNokia$9.14+0.01%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$64.62+0.02%

Questions About ELAN

What is the current price of Elanco Animal Health?

Elanco Animal Health is trading at $26.37 per share.

What is the 52-week range for Elanco Animal Health?

Over the past 52 weeks, Elanco Animal Health has traded between $13.75 and $27.72.

How much debt does Elanco Animal Health have?

As of the most recent reporting period, Elanco Animal Health reported total debt of $3.99B.

How much cash does Elanco Animal Health have on hand?

Elanco Animal Health reported $428.00M in cash and cash equivalents in its most recent financial results.

What is Elanco Animal Health’s dividend yield?

Elanco Animal Health does not currently have a dividend yield.

Elanco Animal Health(NYSE) ELAN

Elanco Animal Health Financials at a Glance

ELAN News

Elanco (ELAN) Q2 Revenue Jumps 5%

Why Elanco Animal Health Stock Was Pure Catnip to Investors This Week

Why Investors Were Barking Loudly About Elanco Animal Health Stock Today

2 Unstoppable Growth Stocks Wall Street Thinks Can Soar by at Least 70%

Got $5,000? Here Are 2 Top Growth Stocks to Buy for July

This Pet Health Stock Is Down After Earnings -- Here's Why

Why Elanco Animal Health Stock Is Falling Today

This Acquisition Could Open a Whole New Market to Elanco

ELAN: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Elanco Animal Health

What Animals Need

Strategic Moves and Growth

A Global Network for Innovation

The Recent Numbers

Bottom Line

ELAN Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Elanco Animal Health Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ELAN

What is the current price of Elanco Animal Health?

What is the 52-week range for Elanco Animal Health?

How much debt does Elanco Animal Health have?

How much cash does Elanco Animal Health have on hand?

What is Elanco Animal Health’s dividend yield?

Premium Investing Services